EP0941733A3 - Procédés d'hinibition de l'exportation de protéines sans séquence de tête à l'aide de glycosides ou d'aglycones cardiaques et de dérivés - Google Patents

Procédés d'hinibition de l'exportation de protéines sans séquence de tête à l'aide de glycosides ou d'aglycones cardiaques et de dérivés Download PDF

Info

Publication number
EP0941733A3
EP0941733A3 EP99100073A EP99100073A EP0941733A3 EP 0941733 A3 EP0941733 A3 EP 0941733A3 EP 99100073 A EP99100073 A EP 99100073A EP 99100073 A EP99100073 A EP 99100073A EP 0941733 A3 EP0941733 A3 EP 0941733A3
Authority
EP
European Patent Office
Prior art keywords
methods
inhibiting
derivatives
cardiac glycosides
protein export
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99100073A
Other languages
German (de)
English (en)
Other versions
EP0941733A2 (fr
Inventor
Robert Z. Florkiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of EP0941733A2 publication Critical patent/EP0941733A2/fr
Publication of EP0941733A3 publication Critical patent/EP0941733A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP99100073A 1996-02-12 1997-02-12 Procédés d'hinibition de l'exportation de protéines sans séquence de tête à l'aide de glycosides ou d'aglycones cardiaques et de dérivés Withdrawn EP0941733A3 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US599895 1996-02-12
US08/599,895 US5891855A (en) 1996-02-12 1996-02-12 Inhibitors of leaderless protein export
PCT/US1997/002237 WO1997028808A1 (fr) 1996-02-12 1997-02-12 Procedes d'inhibition de l'exportation de proteines sans sequence de tete a l'aide de glycosides ou aglycones cardiaques et de derives
EP97906577A EP0828497B1 (fr) 1996-02-12 1997-02-12 Procedes d'inhibition de l'exportation de proteines sans sequence de tete a l'aide de glycosides ou aglycones cardiaques et de derives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP97906577A Division EP0828497B1 (fr) 1996-02-12 1997-02-12 Procedes d'inhibition de l'exportation de proteines sans sequence de tete a l'aide de glycosides ou aglycones cardiaques et de derives

Publications (2)

Publication Number Publication Date
EP0941733A2 EP0941733A2 (fr) 1999-09-15
EP0941733A3 true EP0941733A3 (fr) 1999-12-01

Family

ID=24401543

Family Applications (2)

Application Number Title Priority Date Filing Date
EP97906577A Expired - Lifetime EP0828497B1 (fr) 1996-02-12 1997-02-12 Procedes d'inhibition de l'exportation de proteines sans sequence de tete a l'aide de glycosides ou aglycones cardiaques et de derives
EP99100073A Withdrawn EP0941733A3 (fr) 1996-02-12 1997-02-12 Procédés d'hinibition de l'exportation de protéines sans séquence de tête à l'aide de glycosides ou d'aglycones cardiaques et de dérivés

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP97906577A Expired - Lifetime EP0828497B1 (fr) 1996-02-12 1997-02-12 Procedes d'inhibition de l'exportation de proteines sans sequence de tete a l'aide de glycosides ou aglycones cardiaques et de derives

Country Status (9)

Country Link
US (4) US5891855A (fr)
EP (2) EP0828497B1 (fr)
JP (1) JPH11500454A (fr)
AT (1) ATE183922T1 (fr)
AU (1) AU706644B2 (fr)
CA (1) CA2242245A1 (fr)
DE (1) DE69700464T2 (fr)
ES (1) ES2140215T3 (fr)
WO (1) WO1997028808A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2281925A1 (fr) * 1997-02-26 1998-09-03 Ciblex Corporation Inhibiteurs d'exportation de proteine depourvue de sequence initiale
US6306613B1 (en) 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
US5910484A (en) * 1997-05-30 1999-06-08 The General Hospital Corporation Treatment of ischemic cardiac malfunction
GB9716273D0 (en) 1997-07-31 1997-10-08 Kimberly Clark Ltd Hand cleanser
GB9725480D0 (en) * 1997-12-01 1998-01-28 Univ London Cytokines and their use in the treatment of established chronic infections and cancers
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CZ295108B6 (cs) 1998-03-20 2005-05-18 Benitec Australia Ltd Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen
JP2002536415A (ja) * 1999-02-12 2002-10-29 セルパス インコーポレイテッド 抗腫瘍療法
WO2000063364A2 (fr) * 1999-04-21 2000-10-26 American Home Products Corporation Procedes et compositions pour l'inhibition de la fonction de sequences polynucleotidiques
US6423885B1 (en) * 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
IL138529A0 (en) * 2000-09-18 2003-09-17 Yeda Res & Dev High level expression of heterologous proteins
US7112434B2 (en) * 2001-05-02 2006-09-26 University Of South Florida Vector system for selection of genes encoding secreted proteins and membrane-bound proteins
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
WO2003099011A1 (fr) * 2002-05-28 2003-12-04 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Utilisation de glucosides cardiotoniques pour le traitement de la mucovicidose et autres troubles dependant de il-8
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7560528B2 (en) * 2003-06-20 2009-07-14 Efthimios Ippikoglou Method of producing recombinant DNA molecules
WO2005060951A2 (fr) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Argents anti-neoplasiques, therapies de combinaison et techniques associees
DE102004036047A1 (de) * 2004-07-24 2006-02-23 Bioghurt Biogarde Gmbh & Co. Kg Physiologisch aktive Zusammensetzung
US20080027010A1 (en) * 2004-09-02 2008-01-31 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using Na+/K+-ATPase inhibitors
US20060135442A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20060135468A1 (en) 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
US20060135441A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
EP1812010A2 (fr) * 2004-10-18 2007-08-01 BTG International Limited Utilisation d'inhibiteurs de la na+/k+-atpase et leurs antagonistes
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
WO2007089688A2 (fr) * 2006-01-31 2007-08-09 The University Of Toledo LIGAND Na/K-ATPase
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN101541319B (zh) 2006-10-31 2013-09-18 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
WO2009064657A1 (fr) * 2007-11-13 2009-05-22 Phoenix Biotechnology Inc. Procédé de détermination de la probabilité d'une réponse thérapeutique dans la chimiothérapie anticancéreuse avec un glycoside cardiaque
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR101717301B1 (ko) * 2008-10-14 2017-03-16 네리엄 바이오테크놀로지, 인크. 강심 배당체의 추출방법 및 조성물
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2477494B1 (fr) 2009-09-16 2015-11-11 The University of Toledo Ligands de na/k-atpase, antagonistes ouabaïnes, leurs essais et leurs utilisations
WO2011088210A1 (fr) 2010-01-13 2011-07-21 The University Of Toledo Matériaux et méthodes concernant la sodium/potassium adénosine triphosphatase et src
CN102203112B (zh) 2010-01-15 2014-05-07 苏州润新生物科技有限公司 某些化合物、组合物及方法
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012103810A1 (fr) 2011-02-02 2012-08-09 Suzhou Neupharma Co., Ltd Certaines entités chimiques, compositions et procédés
CN102219821A (zh) * 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途
EP3453713B1 (fr) * 2012-04-29 2021-09-08 Neupharma, Inc. Dérivés bufadiènolides substitués en position 3 par un groupement amine pour le traitement du cancer
WO2013169793A2 (fr) * 2012-05-09 2013-11-14 Ipierian, Inc. Procédés et compositions pour des protéinopathies tdp-43
WO2013171167A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
US9561245B2 (en) * 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
WO2017211979A1 (fr) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinaisons de linagliptine et de metformine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004921A1 (fr) * 1994-08-13 1996-02-22 Hong Keun Chung INHIBITEUR DE LA SECRETION DU TNFα CONTENANT DE LA SYRINGINE OU SON AGLYCONE
US5545623A (en) * 1994-06-10 1996-08-13 Akira Matsumori Method of inhibiting secretion of inflammatory cytokines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5556963A (en) 1994-08-05 1996-09-17 Oklahoma Medical Research Foundation Synthesis of 4-alkoxy-N-acetylneuraminic acid
US5627195A (en) * 1995-04-11 1997-05-06 Massachusetts Eye And Ear Infirmary Treatment for ocular inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545623A (en) * 1994-06-10 1996-08-13 Akira Matsumori Method of inhibiting secretion of inflammatory cytokines
WO1996004921A1 (fr) * 1994-08-13 1996-02-22 Hong Keun Chung INHIBITEUR DE LA SECRETION DU TNFα CONTENANT DE LA SYRINGINE OU SON AGLYCONE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BROOKS ET AL.: "Protein secretion by the rat epididymis can be selectively modified in vitro by local anesthetics, glucose privation, dinitrophenol, ouabain and ionophores", J. ANROL., vol. 5, no. 5, 1984, pages 351 - 360, XP002034262 *
CRUTCHLEY ET AL.: "Monovalent cation dependence of tissue plasminogen activator synthesis by HELA cells", J. BIOL. CHEM., vol. 262, no. 7, 5 March 1987 (1987-03-05), pages 3017 - 3021, XP002034261 *
FLOKIEWICZ ET AL.: "Quantitative export of FGF-2 occurs through an alternative, energy-dependent, non-ER/Golgi pathway", J. CELL. PHYSIOL., vol. 162, no. 3, March 1995 (1995-03-01), pages 388 - 399, XP000676621 *

Also Published As

Publication number Publication date
DE69700464T2 (de) 2000-04-06
EP0828497B1 (fr) 1999-09-01
AU706644B2 (en) 1999-06-17
EP0941733A2 (fr) 1999-09-15
CA2242245A1 (fr) 1997-08-14
JPH11500454A (ja) 1999-01-12
DE69700464D1 (de) 1999-10-07
US6281197B1 (en) 2001-08-28
AU2123197A (en) 1997-08-28
US6107283A (en) 2000-08-22
ES2140215T3 (es) 2000-02-16
ATE183922T1 (de) 1999-09-15
EP0828497A1 (fr) 1998-03-18
WO1997028808A1 (fr) 1997-08-14
US6071885A (en) 2000-06-06
US5891855A (en) 1999-04-06

Similar Documents

Publication Publication Date Title
EP0941733A3 (fr) Procédés d'hinibition de l'exportation de protéines sans séquence de tête à l'aide de glycosides ou d'aglycones cardiaques et de dérivés
NO20002957D0 (no) Behandling med anti-ErbB2-antistoffer
DE69014478T2 (de) Regelungsanordnung für eine sitzheizung.
HK1000786A1 (en) Dna constructs for endogenous gene activation and expression modification.
DK0736532T3 (da) Pyrido[3,2-e]pyrazinoner med antiastmatisk virkning og fremgangsmåde til deres fremstilling
DE68906550D1 (de) Individuelle blattsteuerung fuer helikopter.
NO902750D0 (no) Fremgangsmaate til fremstilling av 3,5,6-substituerte derivater av 1,2-0-isopropyliden-alfa-glukofuranose og mellomprodukter for fremstilling av derivatene.
NO875358L (no) 6-benzoksazinyl- og 6-benzotiazinyl-2,3,4,5-tetrahydropyridazin-3-oner og fremgangsmaate for deres fremstilling.
GR1000519B (el) Παραγωγα ερυθρομυκινης.
AU3524995A (en) Method for treatment of cancers by regulating the activity of ras proteins
DE68900210D1 (de) Pyranobenzoxadiazolderivate, herstellung, verwendung und diese enthaltende zubereitungen.
NO882940D0 (no) Fremgangsmaate for fremstilling av castanosperminestere og glycosider.
IT8721841A0 (it) Metodo per realizzare mobili, particolarmente poltrone, divani o simili, da fogli di feltro trattati con sostanze indurenti e mobili relativi
DK315387A (da) Androst-4-en-3,17-dioner og fremgangsmaade til fremstilling deraf
OA09128A (en) Platinum- (IV) -diamine complex, method for the preparation of this compound, preparation with an anti-tumour action, which contains at least one platinum compound, and shaped preparations with an anti-tumour action.
AU599133B2 (en) Novel substituted (4.2.0.)bicyclooctane derivatives with valuable therapeutic properties
NO903484D0 (no) Substituerte pyrazinderivater og fremgangsmaate for deres fremstilling.
NO894697D0 (no) Penemderivater og fremgangsmaater for deres fremstilling.
NO893565L (no) Etansulfonamidderivater og fremgangsmaate for deres fremstilling.
DK684987A (da) Amycin og derivater deraf, fremgangsmaade til deres fremstilling og deres anvendelse samt mikroorganisme
NO872885D0 (no) 1,3,5-tritianderivater og fremgangsmaate for dens fremstilling.
AU4857796A (en) Sex-specific dna probe for parrots, methods and kits
IT8947916A0 (it) Composizione farmaceutica per il trattamento di protozoosi, particolarmente della tripasonomiasi comprendente d-carnitina o un alcanoil derivato della d-carnitina
IT8560383V0 (it) Pannello o sportello-antina curvo per mobili.
IT1210232B (it) Dispositivo di bloccaggio di ante accoppiate girevoli, specialmente per mobili.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990105

AC Divisional application: reference to earlier application

Ref document number: 828497

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010901